“OC-18 | Effectiveness of fremanezumab up to 12 months in different subgroups of participants: results from the Italian analysis of the PEARL study: Raffaele Ornello,1 Gisella Airola,2 Letizia Curto,3 Diletta Alivernini,4 Chiara Abagnale,5 Pinar Kokturk,6 Yan Tereshko7 | 1Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila; 2Department of Surgical Sciences, Women’s Headache Center, University of Turin; 3Neurology Unit, Department of Clinical and Experimental Medicine, University of Pisa; 4Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Sapienza University of Rome; 5Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome Polo Pontino ICOT, Latina, Italy; 6TEVA Pharmaceuticals Europe B.V., Haarlem, The Netherlands; 7Clinical Neurology, Department of Head-Neck and Neuroscience, Azienda Sanitaria Universitaria Friuli Centrale (ASU FC), Udine, Italy” (2025) Confinia Cephalalgica, 35(S1). doi:10.4081/cc.2025.15815.